Increased expression of interleukin-22 by synovial Th17 cells during late stages of murine experimental arthritis is controlled by interleukin-1 and enhances bone degradation

Arthritis and Rheumatism

Volumn 63, Issue 10, 2011, Pages 2939-2948

  Marijnissen, Renoud J ^a   Koenders, Marije I ^a   Smeets, Ruben L ^b   Stappers, Mark H T ^a   Nickerson Nutter, Cheryl ^c   Joosten, Leo A B ^a   Boots, Annemieke M H ^b,d   Van Den Berg, Wim B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Merck Research Laboratories (MSD)   (Netherlands)

^c PFIZER INC   (United States)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 22; INTERLEUKIN 22 ANTIBODY; INTERLEUKIN 23; MAB 421; MESSENGER RNA; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BONE DEFECT; BONE EROSION; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE CULTURE; LYMPHOCYTE DIFFERENTIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SYNOVITIS; SYNOVIUM; TH1 CELL; TH17 CELL; TH2 CELL;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BONE AND BONES; CELL DIFFERENTIATION; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-23; INTERLEUKINS; JOINTS; MICE; SYNOVIAL MEMBRANE; TH17 CELLS;

EID: 80053510122     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30469     Document Type: Article

References (32)

1. Goronzy JJ, Weyand CM,. T-cell regulation in rheumatoid arthritis. Curr Opin Rheumatol 2004; 16: 212-7. (Pubitemid 38530488)
2. Weyand CM, Goronzy JJ,. T-cell-targeted therapies in rheumatoid arthritis. Nat Clin Pract Rheumatol 2006; 2: 201-10.
3. Isaacs JD,. Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future. Rheumatology (Oxford) 2008; 47: 1461-8.
4. Gutcher I, Becher B,. APC-derived cytokines and T cell polarization in autoimmune inflammation. J Clin Invest 2007; 117: 1119-27. (Pubitemid 46718396)
5. Koenders MI, Kolls JK, Oppers-Walgreen B, van den Bersselaar L, Joosten LA, Schurr JR, et al. Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis. Arthritis Rheum 2005; 52: 3239-47. (Pubitemid 41447107)
6. Koenders MI, van den Berg WB,. Translational mini-review series on Th17 cells: are T helper 17 cells really pathogenic in autoimmunity? Clin Exp Immunol 2010; 159: 131-6.
7. Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004; 50: 650-9. (Pubitemid 38198849)
8. Koenders MI, Devesa I, Marijnissen RJ, Abdollahi-Roodsaz S, Boots AM, Walgreen B, et al. Interleukin-1 drives pathogenic Th17 cells during spontaneous arthritis in interleukin-1 receptor antagonist-deficient mice. Arthritis Rheum 2008; 58: 3461-70.
9. Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, Kang HS, et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 2009; 30: 576-87.
10. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233-40. (Pubitemid 40189432)
11. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003; 198: 1951-7. (Pubitemid 38032126)
12. Wolk K, Witte E, Witte K, Warszawska K, Sabat R,. Biology of interleukin-22. Semin Immunopathol 2010; 32: 17-31.
13. Monteleone G, Pallone F, Macdonald TT,. Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease. Cytokine Growth Factor Rev 2009; 20: 185-91.
14. Dumoutier L, Lejeune D, Colau D, Renauld JC,. Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22. J Immunol 2001; 166: 7090-5. (Pubitemid 32525578)
15. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R,. IL-22 increases the innate immunity of tissues. Immunity 2004; 21: 241-54. (Pubitemid 39094053)
16. Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, Renauld JC,. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line: pathways that are shared with and distinct from IL-10. J Biol Chem 2002; 277: 33676-82.
17. Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A, Bhan AK, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008; 118: 534-44. (Pubitemid 351206544)
18. Ma HL, Liang S, Li J, Napierata L, Brown T, Benoit S, et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 2008; 118: 597-607. (Pubitemid 351206549)
19. Kreymborg K, Etzensperger R, Dumoutier L, Haak S, Rebollo A, Buch T, et al. IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J Immunol 2007; 179: 8098-104.
20. Geboes L, Dumoutier L, Kelchtermans H, Schurgers E, Mitera T, Renauld JC, et al. Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum 2009; 60: 390-5.
21. Ikeuchi H, Kuroiwa T, Hiramatsu N, Kaneko Y, Hiromura K, Ueki K, et al. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum 2005; 52: 1037-46. (Pubitemid 40530109)
22. Nicklin MJ, Hughes DE, Barton JL, Ure JM, Duff GW,. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 2000; 191: 303-12.
23. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006; 203: 2271-9. (Pubitemid 44498362)
24. Stritesky GL, Yeh N, Kaplan MH,. IL-23 promotes maintenance but not commitment to the Th17 lineage. J Immunol 2008; 181: 5948-55.
25. Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y,. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci U S A 2003; 100: 5986-90. (Pubitemid 36576918)
26. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000; 191: 313-20. (Pubitemid 30060920)
27. Abdollahi-Roodsaz S, Joosten LA, Koenders MI, Devesa I, Roelofs MF, Radstake TR, et al. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J Clin Invest 2008; 118: 205-16.
28. Koenders MI, Lubberts E, Oppers-Walgreen B, van den Bersselaar L, Helsen MM, di Padova FE, et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 2005; 167: 141-9. (Pubitemid 40884777)
29. Sonnenberg GF, Nair MG, Kirn TJ, Zaph C, Fouser LA, Artis D,. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J Exp Med 2010; 207: 1293-305.
30. Grevers LC, de Vries TJ, Vogl T, Abdollahi-Roodsaz S, Sloetjes AW, Leenen PJ, et al. S100A8 enhances osteoclastic bone resorption in vitro through activation of Toll-like receptor 4: implications for bone destruction in arthritis. Arthritis Rheum 2011; 63: 1365-75.
31. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL,. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005; 115: 282-90. (Pubitemid 40385470)
32. Jimi E, Nakamura I, Duong LT, Ikebe T, Takahashi N, Rodan GA, et al. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp Cell Res 1999; 247: 84-93. (Pubitemid 29393964)